Patients assigned to STRATTERA in the maintenance phase were generally continued on the same dose used to achieve a response in the open label phase. For PMs, AUC of atomoxetine is approximately 10-fold and Css, max is about 5-fold greater than EMs. W hen doses were normalized to a mg/kg basis, similar half-life, Cmax, and AUC values were observed in children, adolescents, and adults. In some cases, like mine, nothing seems to work ( which I’m told occurs in about 10% of us). I have been getting so little sleep recently (and the sleep I am getting is so low-quality) that I can’t even tell if the Strattera is working or not because my brain is so tired and foggy and out-of-it. I found a sleeping schedule that will allow me to survive a few more weeks on these meds, but I did call my doctor and got a lower dosage. In these clinical trials, no poor metabolizers (0/43) reported seizures compared to 0.1% (1/705) for extensive metabolizers.Commonly observed adverse reactions associated with the use of STRATTERA (incidence of 2% or greater) and not observed at an equivalent incidence among placebo-treated patients (STRATTERA incidence greater than placebo) are listed in Table 4. The heart rate effects could be I would give it at least a couple months before deciding if the insomnia is something you can’t handle because there is a good chance that it’ll … Don’t know what to do about that one. Patients who were pubertal (girls >8 to ≤13 years old, boys >9 to ≤14 years old) or late pubertal (girls >13 years old, boys >14 years old) had average weight and height gains that were close to or exceeded those predicted after three years of treatment.Growth followed a similar pattern in both extensive and poor metabolizers (EMs, PMs). While it is difficult to know the precise risk of sexual dysfunction associated with the use of STRATTERA, physicians should routinely inquire about such possible side effects.The following adverse reactions have been identified during post approval use of STRATTERA. In pediatric short-term controlled clinical trials, 21/1308 (1.6%) of atomoxetine patients versus 9/806 (1.1%) of placebo-treated patients spontaneously reported treatment emergent hostility-related adverse events (overall risk ratio of 1.33 [95% C.I. And sometimes I troll the internet late at night and gaze at insomnia websites – but that’s BAD!!! That being said I would suggest that you consult your prescribing physician. 2, synthetic yellow iron oxide, titanium dioxide, red iron oxide. Dosage adjustment of STRATTERA may be necessary when coadministered with potent CYP2D6 inhibitors (e.g., paroxetine, Physicians should instruct their patients to read the Medication Guide before starting therapy with STRATTERA and to reread it each time the prescription is renewed.Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with STRATTERA and should counsel them in its appropriate use. The mean final dose of STRATTERA for both studies was approximately 1.6 mg/kg/day. STRATTERA was administered as a divided dose in the early morning and late afternoon/early evening and titrated according to clinical response in a range of 60 to 120 mg/day. The chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride. Should I change the time I take it or just wait it out and hope it stops (I’m not sure how much longer my brain will last, though)? Dosage adjustment is recommended for patients with moderate or severe hepatic insufficiency [see Ethnic origin did not influence atomoxetine disposition (except that PMs are more common in Caucasians).Atomoxetine administered in a flexible dose range of 0.5 to 1.5 mg/kg/day (mean dose of 1.3 mg/kg/day) and placebo were compared in 148 randomized pediatric (age 717 years) subjects with a In two post-marketing, double-blind, placebo-controlled trials, it has been demonstrated that treating patients with ADHD and comorbid anxiety disorders with STRATTERA does not worsen their anxiety.In a 12-week double-blind, placebo-controlled trial, 176 patients, aged 8-17, who met DSM-IV criteria for ADHD and at least one of the anxiety disorders of In a separate 16-week, double-blind, placebo-controlled trial, 442 patients aged 18-65, who met DSM-IV criteria for adult ADHD and There is limited clinical trial experience with STRATTERA overdose. In clinical trials with children and adolescents, administration of STRATTERA with food resulted in a 9% lower Cmax.The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water. Visit the capsule, blue/white, imprinted with Lilly 3228, 25 mgcapsule, gold/white, imprinted with Lilly 3238, 18 mgcapsule, blue/yellow, imprinted with Lilly 3239, 60 mgcapsule, brown/white, imprinted with Lilly 3250, 80 mgcapsule, white, imprinted with TEVA 7590, TEVA 7590capsule, brown, imprinted with TEVA 7589, TEVA 7589capsule, yellow/white, imprinted with TEVA 7591, TEVA 7591capsule, blue/white, imprinted with TEVA 7592, TEVA 7592capsule, blue/yellow, imprinted with TEVA 7594, TEVA 7594capsule, brown/white, imprinted with TEVA 7588, TEVA 7588capsule, gold/white, imprinted with Lilly 3238, 18 mgcapsule, blue/white, imprinted with Lilly 3228, 25 mgcapsule, blue/yellow, imprinted with Lilly 3239, 60 mgcapsule, brown/white, imprinted with Lilly 3250, 80 mgCopyright © 2020 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including STRATTERA should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening.